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Ageing is a major risk factor for the development of many diseases, prominently 
including neurodegenerative disorders such as Alzheimer and Parkinson disease. A 
hallmark of many age-related diseases is the dysfunction in protein homeostasis 
(proteostasis), leading to the accumulation of protein aggregates. In healthy cells, a 
complex proteostasis network, comprising molecular chaperones as well as 
proteolytic machineries and their regulators, operates to ensure the maintenance of 
proteostasis. These factors coordinate protein synthesis with polypeptide folding, the 
conservation of protein conformation and protein degradation. However, sustaining 
proteome balance is a challenging task in the face of various external and endogenous 
stresses that accumulate during ageing. These stresses lead to the decline of 
proteostasis network capacity and proteome integrity. The resulting accumulation of 
misfolded and aggregated proteins affects in particular postmitotic cell types such as 
neurons, manifesting in disease. Recent analyses of proteome-wide changes that occur 
during ageing inform on strategies to improve proteostasis. The possibilities of 
pharmacological augmentation of the capacity of proteostasis networks hold great 
promise for delaying the onset of age-related pathologies associated with proteome 





Most proteins must fold into well-defined three-dimensional structures and need to 
remain folded throughout their life-time in order to perform their biological functions. 
Moreover, the abundance of each of the thousands of different proteins in a 
mammalian cell must be carefully controlled. We now appreciate that this state of a 
balanced proteome, referred to as protein homeostasis (or ‘proteostasis’1), depends on 
an extensive network of molecular chaperones, proteolytic systems and their 
regulators, comprising approximately 2000 proteins in human cells2. Understanding 
the organization of this network and its regulation in response to external and 
endogenous stresses is of fundamental importance in biology and medicine, as the 
failure to maintain proteostasis is associated with ageing and numerous degenerative 
diseases3,4. 
The proteostasis network serves to ensure that correctly folded proteins are 
generated at the right time and cellular location, and in amounts allowing 
stoichiometric assembly in case of oligomeric protein complexes. Additionally, it 
prevents proteins from misfolding and aggregation. Beyond regulation of folding, the 
proteostasis network also ensures that superfluous and misfolded protein species are 
removed, either by autophagy or degradation mediated by the proteasome. Together, 
these mechanisms avoid the accumulation of protein aggregates, which can be 
potentially toxic (Fig. 1a). Key effectors of the proteostasis network are molecular 
chaperones, which ensure proper protein folding and conformational maintenance and 
cooperate with the degradation machinery. Proteostasis is disturbed in various 
pathologic conditions, prominently including diseases associated with the old age, 
such as neurodegenerative disorders. This suggests that the capacity of the 
proteostasis network declines with ageing.  
4 
 
Recent advances in transcriptome and proteome analysis now make it possible 
to quantify and measure changes in thousands of different transcripts and proteins. 
Applying these techniques to the studies of ageing in model organisms, such as the 
nematode Caenorhabditis elegans, has provided us with new insight into the decline 
of the proteome during ageing and enables us to identify critical components of the 
proteostasis network that may be amenable to pharmacological manipulation. 
In this Review we discuss our present understanding of the organization of the 
proteostasis network and its role in health and disease. We describe the age-dependent 
changes in the soluble and insoluble proteome gathered from studies of model 
organisms, and we summarize current concepts of aggregate toxicity in 
neurodegenerative diseases and other pathologies associated with ageing. The 
prospects of targeting proteostasis networks to reduce the burden of toxic protein 
aggregates and hamper the development and/or progression of degenerative diseases 
associated with ageing will also be discussed. 
 
The proteostasis network 
Maintaining a balanced proteome requires cells to coordinate the functions of three 
interlinked arms of the proteostasis network: protein synthesis and folding, 
conformational maintenance and degradation (Fig. 1a). 
 
Protein synthesis and folding. 
The proteomes of eukaryotic cells are highly complex, ranging from ~6,000 different 
proteins in fungi5 to over 10,000 proteins in human cells6, with proteome composition 
varying between cell types and tissues. Recent large-scale sequencing data indicate 
the presence of a high number of single nucleotide variants in protein coding regions 
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in the human population7. Mutations can affect protein stability and folding kinetics8, 
possibley resulting in metastable proteins that engage components of the proteostasis 
network9,10. Proteins also vary greatly in abundance, from fewer than 50 copies per 
cell in case of certain transcription factors up to more than 107 molecules for histones, 
cytoskeletal or ribosomal proteins11,12. Protein abundance must be carefully controlled 
to support cell signalling, the proper flux of substrates through metabolic pathways 
and to allow the stoichiometric assembly of large macromolecular machines, such as 
ribosomes or mitochondrial respiratory chain complexes. 
The majority of newly-synthesized proteins must fold into defined three-
dimensional structures in order to attain biological function, with the notable 
exception of proteins with intrinsically disordered regions that may acquire structure 
only when interacting with partner molecules13,14. Generally, the folded (or native) 
states of proteins are thermodynamically favorable and all the information necessary 
for folding is contained within the amino acid sequence of the newly-synthesized 
polypeptide chain. However, proteins must navigate a complex energy landscape 
during folding, putting them at risk of adopting kinetically stable (meaning, 
populating local energy minima) non-native structures (Fig. 1b). These misfolded 
states also tend to engage in non-productive intermolecular interactions, forming 
aggregates that may be thermodynamically more stable than the native state. While 
the folding process was originally thought to occur spontaneously, we now know that 
many proteins, especially those with more complex structures and/or containing 
multiple domains, require molecular chaperones to fold efficiently and at a 
biologically relevant time scale. We define a molecular chaperone as any factor that 
interacts with and aids in the folding or assembly of another protein without being 
part of its final structure15. Mechanistically, chaperones prevent aggregation and 
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promote folding through ATP-dependent and independent mechanisms of protein 
binding and release (for recent reviews see refs.16-20). They are classified into different 
protein families - small heat shock proteins (sHSP), HSP60, HSP70, and HSP90 
(Table 1) - and typically recognize exposed hydrophobic amino acid residues and 
unstructured polypeptide backbones in their substrate proteins, which are unifying 
features of non-native conformation. In some cases electrostatic interactions between 
chaperones and clients also have a role21,22. Chaperones that participate broadly in the 
folding of newly-synthesized proteins (de novo folding) act during and after 
translation to prevent (or reverse) misfolding and aggregation (Fig. 1a and 1b). 
Approximately two thirds of proteins must be transported from their site of 
synthesis in the cytosol to their functional location in a specific subcellular 
compartment23. For proteins destined for the endoplasmic reticulum (ER) and further 
for the secretory pathway or for the mitochondria, cytosolic chaperones prevent 
premature folding before the polypeptide reaches its target organelle and shield 
transmembrane regions from the aqueous cytosol18,24. Binding of organellar 
chaperones at the trans-side of the membrane may then provide the driving force for 
translocation across the membrane25,26. Proteins destined for the nucleus and 
peroxisomes, and so-called tail-anchored proteins fold before transport. 
 
Maintenance of conformational stability. 
The folded structures of proteins are in most cases only marginally stable. This 
implies that a substantial proportion of protein species may populate (partially) 
unfolded states (Fig. 1b), especially in the presence of additional destabilizing factors, 
such as mutations or external stresses (e.g. elevated temperature, heavy metals or 
presence of reactive oxygen species). Polypeptides in non-native conformations, i.e. 
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nascent chains, folding intermediates and misfolded states, tend to aggregate owing to 
the exposure of hydrophobic amino acid residues and unpaired -strands. Aggregation 
removes proteins from the pool of functionally active molecules, and thereby leads to 
a reduction of function of the aggregated protein. Moreover, aggregate species may be 
cytotoxic in a manner unrelated to their biological role, as will be discussed below. 
To avoid the accumulation of misfolded proteins and cytotoxic protein 
aggregation, the proteostasis network contains molecular chaperones, for many of 
which transcription is induced under stress conditions through compartment-specific 
signalling pathways. The main cytosolic response to stress is the heat shock response, 
which is controlled by a group of transcription factors known as heat shock factors. 
By binding to heat shock elements in promotor regions these factors control various 
genes encoding chaperones (heat shock proteins) and other factors of the proteostasis 
network. The best studied of these is heat-shock transcription factor 1 (HSF1). In non-
stressed cells HSF1 is present in an inactive complex with the chaperones HSP90 (ref. 
27) and HSP70 (ref. 28). The presence of non-native proteins is thought to result in 
titration of these chaperones away from HSF1, which then allows HSF1 to trimerize 
and induce the transcription of heat shock protein-encoding genes29. Concomitantly 
with the induction of members of the proteostasis network, general protein synthesis 
is attenuated upon stress, which reduces the production of new clients of the 
proteostasis network. Once the proteotoxic stress has ceased and sufficient free 
chaperone capacity is reestablished, these factors rebind HSF1 and the system returns 
to balance30. Similar signalling pathways to counter aberrantly folded and/or unfolded 
proteins are present in the ER and in mitochondria31,32. 
With few exceptions, homologues of stress-inducible chaperones are also 
constitutively expressed both in the cytosol and within organelles, including the HSP 
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families mentioned above16,18. They form cooperative networks to maintain non-
native protein species in solution and mediate their refolding to achieve functional 
structures (remodelling; Fig. 1a). A distinct set of chaperones function in the 
conformational maintenance of the secreted proteome in the extracellular space33. 
 
Protein degradation. 
In combination with controlled protein synthesis, regulated degradation of proteins is 
an important mechanism to adjust the levels of functional proteins, thereby regulating 
important cellular processes such as mitosis34 and adapting protein levels in response 
to environmental changes35,36. Protein degradation is also a key mechanism to avoid 
accumulation of misfolded or faulty protein species, including mutant proteins and 
unassembled subunits of multiprotein complexes. Proteins are degraded by two major 
proteolytic pathways, the ubiquitin proteasome system (UPS) and the 
autophagosomal–lysosomal pathway37-39. While degradation by the UPS requires 
ATP-dependent unfolding of single substrate proteins, the autophagy pathway allows 
the degradation of protein aggregates and whole organelles. In both proteolytic 
systems, molecular chaperones cooperate in the recognition of misfolded protein 
species and help to maintain them in a degradation competent state40-42. 
 In targeting aberrant proteins for degradation, the UPS cooperates with the 
major cytosolic chaperone systems, HSP70 and HSP90, and with chaperone cofactors 
containing E3 ubiquitin ligase activity, such as the carboxy terminus of HSP70-
interacting protein (CHIP). CHIP interacts via its tetratricopeptide repeat (TPR) 
domain with the carboxy-terminus of HSP70 or HSP90 to ubiquitylate folding-
incompetent proteins — characterized by a long chaperone residence time43 — which 
targets them to the proteasome. In addition, CHIP has the ability to prevent 
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aggregation in the absence of these chaperones44. Other components of the UPS, the 
yeast E3 ligase San1 and the metazoan E2 ubiquitin-conjugating enzyme UBE2O also 
have inbuilt chaperone properties and bind surplus or misfolded proteins directly45,46. 
UBE2O mediates ubiquitylation without a separate E3 ligase and in reticulocytes 
mediates the removal of α-globin subunits that failed to assemble with -globin in the 
process of haemoglobin assembly46. In other proteins, co-translational modifications, 
such as N-terminal acetylation47, function as signals for UPS-mediated degradation 
when exposed in unassembled subunits. Chaperones also assist in the degradation of 
misfolded proteins by autophagy48. HSC70 (the constitutively expressed member of 
the HSP70 family) and its co-chaperone BAG3 are involved in the degradation of 
aggregates in a process known as chaperone-assisted selective autophagy 49,50. HSC70 
also participates in the degradation of soluble cytosolic proteins containing a KFERQ 
sequence motif by chaperone-mediated autophagy in lysosomes51,52 and endosomal 
microautophagy in late endosomes and multivesicular bodies 42,53. 
 
Sources of misfolded protein species 
Misfolded protein species originate from multiple sources and pose a constant danger 
to the cell. Conformational stress conditions, such as heat stress, oxidative stress54 or 
exposure to toxic agents like cadmium55 may cause a subset of proteins to unfold, 
which increases their risk of aggregating. In contrast to proteins with intrinsically 
disordered regions, some of which inherently possess a high capacity for toxic 
aggregation, this unfolding step is necessary for the aggregation of globular proteins 
such as superoxide dismutase 1, which is associated with amyotrophic lateral sclerosis 
(ALS)56. Moreover, the protein synthesis and folding process is imperfect, despite the 
presence of abundant chaperone systems, and it has been estimated that 5-30% of all 
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newly-synthesized proteins do not properly fold and need to be targeted for 
immediate degradation57-59. It is well established that folding efficiencies are 
substantially lower for specific proteins, such as the cystic fibrosis transmembrane 
conductance regulator (CFTR) and other multi-pass membrane proteins. In the case of 
CFTR, only ~25% of synthesized protein matures to the functional chloride channel, 
with disease-causing mutations reducing folding efficiency even further60,61. For some 
mutations of superoxide dismutase 1 that are associated with familial ALS, it has been 
shown that initial folding steps are delayed, generating aggregation-prone folding 
intermediates62. 
Defective mRNAs are another notable source of aberrant protein products. 
Translation of mRNAs lacking a stop codon (so-called non-stop mRNAs, arising from 
truncation or premature cleavage of the transcript and polyadenylation) results in 
ribosome-stalled polypeptide chains that are folding-incompetent. These chains must 
be removed by ribosome quality control (RQC) machinery and proteasomal 
degradation63 (see Box 1) to avoid aggregation64-66. The importance of the RQC 
pathway is exemplified by the fact that its failure is associated with age-dependent 
neurodegeneration in a mouse model67. Likewise, tRNA availability may limit 
translation rates, resulting in protein aggregation, perhaps by increasing the likelihood 
of misreading or frameshifts, or by increasing the risk that nascent chains occupy non-
productive folding intermediates68.  
Inefficient import into the target organelles, for example into mitochondria or 
the ER, will cause cytosolic accumulation of these proteins and constitutes another 
cause of proteotoxicity69. Many secretory proteins require the oxidizing environment 
of the ER for disulfide bond formation and consequently fail to fold in the reducing 
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environment of the cytosol, generating potentially toxic species that need to be 
eliminated70.  
 
Pathology of protein aggregates  
More than 100 years ago, Alois Alzheimer described the appearance of protein 
“plaques” in the cerebral cortex of a 56 year old patient71. Protein aggregate deposits 
in fibrillar (amyloid -like) form are now widely recognized as a hallmark of many 
neurodegenerative diseases and other mostly age-dependent pathologies, such as type 
II diabetes72,73. It is generally believed that aggregate formation confers a toxic 
property to the disease protein (‘toxic gain of function’). This contrasts with other 
diseases associated with protein misfolding, where the defect is often due to mutations 
that cause loss of function74. Cystic fibrosis is one of the most prominent examples of 
this latter group of diseases75. 
 
Formation of pathological aggregates. 
The process of pathological aggregation is characterized by the formation of amyloid 
fibrils as the end point. Intermediates in this process include soluble oligomeric and 
protofibrillar states that are structurally less ordered than the fibrils and are thought to 
contribute strongly to toxicity. Amyloid fibrils are characterized by ordered cross-β 
structure, i.e. parallel or anti-parallel β-strands running perpendicular to the long fibril 
axis, and have distinct tinctorial properties76-79. Fibrils form via a nucleation-
dependent polymerization pathway, often associated with a long lag-time80. Several 
possible microscopic processes underlie the characteristic sigmoidal aggregation 
curves: primary nucleation of monomers in solution or on surfaces, elongation of 
fibrils through monomer addition to fibril ends, secondary nucleation of oligomers on 
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the surface of already existing fibrils and fibril breakage73,81,82. Preformed fibrils or 
fragments thereof may function as seeds for new, accelerated fibril formation. In 
addition, prion-like cell-to-cell propagation of such seeds is thought to cause the 
spreading of aggregates in the brains of patients suffering from Alzheimer or 
Parkinson disease83-86. 
Notably, amyloid fibrils are not necessarily harmful to cells, as demonstrated 
by an increasing list of non-disease related amyloids with various cellular functions87, 
including the Curli fibrils of Escherichia coli that mediate the attachment of virulent 
bacteria to epithelial surfaces88 and the mammalian premelanosome protein Pmel17 
that provides a template for melanin polymerization89. Rather, toxicity arises when 
various aggregation intermediate states, primarily soluble oligomers (non-fibrillar or 
proto-fibrillar species), are formed during the process of fibril assembly. In support of 
this view, ‘functional amyloids’ appear to have been optimized in evolution so that 
their formation is associated with a minimal number of aggregation intermediates90,91. 
How this is achieved is a subject of ongoing research. Soluble oligomers are thought 
to display characteristic structural properties, independent of sequence78,92. They are 
structurally dynamic and expose hydrophobic amino acid residues and unpaired β-
strands to the solvent, features that are largely buried in ordered fibrils. These 
properties of oligomers confer a high degree of interactivity with cellular proteins and 
membranes93-96. However, amyloid fibrils and amorphous aggregates may also engage 
in aberrant interactions with proteins and membranes. The exact differences in 
amount and nature of the interactions of these various aggregate species remain to be 
established. 
A special case of disease-relevant protein aggregation involves liquid–liquid 
phase separation of certain proteins containing low complexity domains, often with 
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prion-like properties97-99. In this process a homogeneous solution of molecules 
spontaneously separates (‘demixes’) into two coexisting liquid phases — a condensed 
phase (a non-membrane bound droplet-like compartment) and a depleted phase (the 
bulk solution). The interface of the condensed droplet forms a boundary that allows 
the selective passage of some molecules but not others. These phase-separated 
assemblies provide a general regulatory mechanism to compartmentalize biochemical 
reactions within cells, enhancing biological reactions or sequestering factors that are 
temporarily not required99,100. Notably, some of these assemblies over time undergo a 
maturation process, which involves a liquid-to-solid phase transition with the 
concomitant formation of structures reminiscent of pathological aggregates. These 
processes can be accelerated by mutations, post-translational modifications, changes 
in the properties of the solution (salt concentration), metabolic state or in response to 
increasing molecular concentration98,101,102. Thus, phase separation could promote 
increased rates of nucleation and/or growth of amyloid-like fibres. A prominent 
example is the aggregation of the predominantly nuclear RNA-binding proteins FUS 
and TDP-43 in the cytosol, mutations of which are associated with ALS102,103. Age-
related changes in the proteome (changes of the balance between synthesis and 
degradation as well as decline in folding capacity; see also below) and metabolome 
(changes in the local microenvironment) can lead to aberrant phase transitions that 
may be a key driver of ageing and disease104. 
 
Mechanisms of aggregate toxicity. 
How aggregates cause toxicity, cellular dysfunction and eventual death is only 
partially understood. A large body of evidence points to multiple mechanisms acting 
in parallel, with specific modes of toxic function being more pronounced in certain 
14 
 
disease proteins and cell types. Two principal activities at the cellular level can be 
distinguished: damaging effects on lipid membranes and aberrant interactions with 
macromolecules, primarily soluble or membrane-associated proteins and RNA 
molecules (Fig. 2). 
Experiments in cell culture and studies with model lipid membranes indicate 
that soluble oligomers (ranging in size roughly between 20-60 molecules) have the 
ability to disrupt the integrity of membrane structures in the neuronal synapse and 
other cellular locations by forming pore-like structures105-107 (Fig. 2a). Fibrils, though 
exposing less hydrophobic surfaces than oligomers, may nevertheless have the 
capacity to deform or even pierce endomembranes, as shown in vitro79,108 and 
suggested by recent observations of aggregate deposits in situ by cryo-electron 
tomography109 (Fig 2a). 
The other well-supported mechanism of proteotoxicity relates to the ability of 
aggregates to engage in aberrant interactions with multiple cellular proteins (Fig. 2b), 
such as nucleo-cytoplasmic transport factors, ribonucleoproteins and other proteins 
with key functions96,110-114. The proteins bound by the aggregates tend to be 
metastable and characteristically contain intrinsically disordered regions or low 
complexity domains96,111,115-118. Based on recent studies, these interactions are 
primarily initiated by protein oligomers and are first dynamic in nature, but may result 
in the stable sequestration of target molecules in insoluble aggregate deposits96,114,115. 
Importantly, owing to their ability to recognize and bind misfolded proteins, certain 
chaperones and other proteostasis components are also prone to be sequestered by 
aggregates. As a result, chaperones and regulatory chaperone cofactors, such as 
HSC70 and certain HSP40 regulators of the HSP70 system, are substantially depleted 
from the soluble, active pool, which negatively impacts the proteostasis network by 
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reducing its overall strength and thereby contributes to further aggregate 
accumulation64,119,120. Sequestration of regulatory proteostasis network components 
also impedes the capacity of cells to induce an effective heat shock response115,121. 
Interestingly, the sustained presence of misfolded proteins may lead to a chronic 
stress response activation that is ineffective in preventing aggregation. This state has 
been referred to as a maladaptive stress response and has been shown to impact 
protein folding and exacerbate disease pathology122.  
 Expression of aggregation-prone proteins has also been shown to impair 
protein degradation via autophagy123 and the UPS124-127. Indeed, some disease 
aggregates, such as those formed by C9orf72-encoded glycine-alanine dipeptide 
repeat proteins associated with ALS126 display a remarkably high association with 
proteasome complexes, reflecting an (apparently unproductive) attempt of the UPS to 
degrade aggregate material.  
Overall, protein aggregates have the capacity to interfere with the proper 
function of the proteostasis network. The resulting reduction of available proteostasis 
network capacity increases protein misfolding, setting in motion a vicious feed-
forward cycle that may lead to proteostasis collapse128 (Fig. 2b). 
 
Means of counteracting proteotoxicity 
The functional proteostasis network antagonizes the build-up of aggregates or strives 
to neutralize their toxic effects. This may be achieved by fundamentally different 
strategies. Prevention of aggregation is a primary function of molecular chaperones 
and is achieved by binding of aggregation-prone folding intermediates, followed by 
their refolding or degradation. Preexistent aggregates may be shielded by chaperones 
to block harmful interactions, or be removed by disaggregation or autophagy. 
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Alternatively, toxic aggregate species, such as soluble oligomeric species, may be 
actively converted to large inclusion bodies (containing amorphous or fibrillar 
aggregates), thereby reducing their reactive surfaces for toxic interactions with 
cellular components (Fig. 3).  
 
Chaperone mediated prevention of amyloid formation. 
Chaperone systems interfere with amyloid-like aggregation at different kinetic phases 
of fibril formation. As a result, aggregation may either be completely prevented or the 
equilibrium between aggregate species changed129. Consistent with its central role in 
the chaperone network, the HSP70–HSP40 system has been shown to inhibit primary 
nucleation of fibril assembly and fibril elongation of polyglutamine (polyQ) 
expansion proteins like huntingtin (Htt; mutants of which cause Huntington disease), 
α-synuclein (associated with Parkinson disease) and other neurodegenerative disease 
proteins130-134. HSP40 components have an important role in this process and recruit 
HSP70 to aggregation-prone proteins134,135. The chaperones perform this function by 
interacting with hydrophobic sequence elements of the aggregating disease proteins. 
The cylindrical chaperonin TRiC/CCT also acts to inhibit aggregation of various 
disease proteins129,136,137 and has been shown to specifically prevent the formation of 
toxic oligomers of Htt129. Other chaperones, such as the small BRICHOS domain, 
may coat the surface of fibrils and inhibit secondary nucleation138, thereby interfering 
with the production of toxic oligomers. 
 
Chaperone-mediated disaggregation. 
Interfering with the production of disease protein halts disease progression and allows 
for the dissociation of preexisting aggregates, as shown in mouse models of 
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Huntington disease139,140. Indeed, cells contain specialized chaperone machineries that 
can dissociate aggregates in an ATP-dependent process. In yeast and other fungi, 
AAA+ chaperones of the Hsp100 family mediate protein disaggregation in concert 
with Hsp70 and Hsp40 141,142. In metazoans, which lack Hsp100 family members, a 
network of chaperones including HSP70 and the nucleotide exchange factor HSP110 
(an HSP70 homolog) mediates protein disaggregation143,144. Notably, disaggregation 
entails the danger of generating oligomeric, potentially toxic, protein species and 
therefore must be coupled to the degradation of aggregate material via the UPS or the 
autophagy–lysosomal pathway. How this timely degradation is achieved remains to 
be investigated.  
 
Formation of inclusion bodies. 
In conditions of limited proteostasis capacity, cells may reduce aggregate load by 
actively sequestering smaller aggregates into larger deposits (Fig. 3). Upon heat-
stress, the chaperone Hsp42, a small HSP (sHSP), mediates the rapid concentration of 
misfolded proteins into small cytosolic aggregate foci (also referred to as Q-
bodies)145-148, which may give rise to larger inclusions. Interestingly, this “aggregase” 
function depends on a prion-like, intrinsically disordered sequence of Hsp42 (ref. 149). 
A related protein, Btn2, fulfills a similar role in the nucleus146. Association of sHSP 
with amorphous aggregate deposits is frequently observed and may shield aggregate 
surfaces that are available for interactions and facilitate subsequent disaggregation150.  
Inclusion bodies are actively formed in yeast in the vicinity of the vacuole and 
the nucleus, as well as in the nucleus146,151. Mammalian cells concentrate aggregated 
proteins in so-called “aggresomes” at the microtubule-organizing centre in an ATP 
and microtubule dependent process152. Inclusion bodies may function as a sink to 
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lower the level of small diffusible oligomers, and thereby reduce the reactive surface 
and the amount of bound chaperones, consistent with the reduced capacity of 
aggregate material in inclusion bodies to engage in aberrant interactions96,114. Indeed, 
the presence of inclusion bodies correlates with improved cell survival in cellular 
models of neurodegenerative disease153. Concentration of aggregates in an inclusion 
body can also facilitate the asymmetric inheritance of damaged proteins in dividing 
cells (Fig. 3). This process generates one daughter cell that contains the majority of 
the aggregated proteins, and a second “rejuvenated” daughter154. The lack of cell 
division in postmitotic cells such as neurons can therefore help to explain why these 
cells are especially vulnerable to pathologies associated with protein aggregation. 
Directing aggregation-prone material to specific organelles has been suggested 
as yet another strategy to reduce toxicity155,156 (Fig. 3). For example, the aggregates of 
specific disease proteins have been found to be more toxic in the cytosol than the 
nucleus (and vice versa) and a recent report suggested that upon heat stress, certain 
misfolded proteins can be detected inside mitochondria, although they lack 
mitochondrial targeting sequences157. The physiological significance and the 
underlying mechanism of this observation remain unclear, but it is noteworthy that 
both mitochondria and ER have a higher tolerance for the presence of aggregation-
prone proteins than the cytosol. This is presumably due to increased capacity of these 
compartments to maintain aggregation-prone disease proteins in a soluble state due to 
the presence of compartment-specific chaperone systems158,159. 
 
Age-dependent proteostasis decline 
The age-dependent decline in the ability of cells to maintain a functional proteome is 
regarded as a major driver of age-related cellular dysfunction and degenerative 
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diseases2-4,160,161. The biological reasons why the proteostasis network deteriorates are 
complex, but probably relate to a lack of evolutionary pressure for proteome 
maintenance beyond the point when organisms have produced progeny and passed 
their genome to the next generation. In model organisms such as C. elegans, a 
controlled ageing programme is thought to allocate organismal resources to 
reproduction rather than proteome maintenance162 and most genetic manipulations 
that extend lifespan and improve proteostasis are associated with reduced fecundity 
(see Box 2). 
Recent systemic proteome analyses throughout the lifespan of C. elegans 
provided insight into age-dependent changes in proteome composition163-167. Large-
scale proteome profiling of about 5,000 different proteins revealed extensive 
proteome remodelling and the development of severe proteome imbalance during 
ageing, characterized by extensive changes in the abundance of proteins166. About one 
third of the quantified proteins were found to increase or decrease in abundance by at 
least 2-fold after day 6 of adulthood. These global changes are thought to be caused 
(at least in part) by a dysregulation in miRNA-mediated post-transcriptional gene 
regulation166,168. This age-dependent proteome remodelling was substantially less 
pronounced in long-lived daf-2 mutant worms defective in insulin/insulin-like growth 
factor signalling (see Box 2), indicative of an improved capacity of the proteostasis 
network. The extensive proteome remodelling observed during ageing in C. elegans 
differs from observations in tissues of aged mice, where only minor proteomic 
changes were detected with a similar experimental approach169. Thus, mammals 
appear to devote greater resources to maintaining proteome balance, limiting age-
dependent cell-type and organelle-specific proteome changes170. 
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A hallmark of the ageing proteome is the loss of protein solubility and the 
accumulation of aggregates. C. elegans has been used extensively as a model to study 
this process163,164,166. A recent quantitation of ~2,100 aggregating proteins166 tested 
the view that proteins have been optimized in evolution to maintain solubility at their 
physiological concentrations (prior to age-dependent proteome deregulation), but 
aggregate when exceeding that concentration171 (referred to as critical concentration). 
The analysis confirmed that proteins of low abundance tend to have higher 
aggregation propensities during ageing compared to abundant proteins. Nevertheless, 
highly abundant proteins were found to predominantly contribute to total aggregate 
load, despite their higher intrinsic solubility166. Apparently, the solubility of abundant 
proteins is insufficient to protect them from age-dependent aggregation since the 
proteome and proteostasis network changes associated with ageing (see the following 
paragraph) result in these proteins eventually exceeding the critical concentration, a 
phenomenon referred to as supersaturation171,172.  
During ageing the proteostasis network becomes increasingly burdened by 
increasing loads of misfolded proteins and proteins that have been damaged by 
oxidative stress173, particularly in non-dividing, long-lived cells such as neurons9,174. 
In addition, at least in human brain, the expression of ATP-dependent chaperones is 
repressed during ageing, which may further promote protein misfolding and 
aggregation (Fig. 2b)175. Once the capacity of the proteostasis network drops below a 
critical level, aggregation-prone proteins can no longer be maintained in a soluble 
state. As shown in cellular and organismal models, this threshold is lowered in the 
presence of additional forms of stress, such as proteasome inhibition176 or the 
presence of mutations that structurally destabilize specific proteins and promote 
21 
 
misfolding10,177.The additional pressure on the proteostasis network causes further 
protein aggregation in a positive feedback loop125,128 (Fig. 2b). 
Notably, stem cells are more resistant to age-dependent proteostasis network 
decline than differentiated cells. It has been demonstrated that human embryonic stem 
cells exhibit elevated levels of proteasome activity for degrading misfolded 
proteins178. Furthermore, human pluripotent stem cells support the efficient assembly 
of the TRiC/CCT chaperonin complex, apparently by enhancing the expression of one 
of its eight subunits, CCT8 (ref. 179), which limits complex assembly when present in 
substoichiometric amounts. Asymmetric division of stem cells might also have a role 
in maintaining a balanced proteome, with the differentiating cell inheriting the 
damaged proteins180-182. These mechanisms may contribute to the maintenance of 
stem cells throughout the animal lifespan. Interestingly, the neural stem cell pool in 
the brain of adult mice comprises quiescent and activated populations with differences 
in their proteostasis network. While activated stem cells have active proteasomes, 
quiescent stem cells were recently shown to rely on large lysosomes for aggregate 
removal. Lysosomal damage accrued during ageing may reduce the ability of 
quiescent cells to dispose of aggregates and to activate181. 
 
Pro-longevity adaptations 
Studies in model organisms including C. elegans, Drosophila melanogaster and 
mouse indicate that the ability of the organism to maintain proteostasis correlates 
strongly with both lifespan and healthspan (i.e. the time during which the organism 
maintains its functional capacity). Accordingly, adaptations in each arm of the 
proteostasis network (Fig. 1a), either genetic or through environmental effects, have 
been shown to prolong lifespan. For example, inhibition of the insulin/insulin-like 
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growth factor signalling pathway (daf-2 mutant in C. elegans), the major lifespan 
extending manipulation in the worm183,184, results in a profound upregulation of stress 
resistance through transcriptional activation of chaperone pathways and increased 
defence against oxidative stress (Box 2).  
 
Changes in protein synthesis and degradation. 
Protein synthesis is a primary node of proteostasis control and its regulation is critical 
for cell growth and maintenance of intracellular protein pools. Notably, with 
increasing age, rates of protein synthesis tend to decline165,185,186. As shown in 
C. elegans, the levels of both cytosolic and mitochondrial ribosomes undergo 
substantial reduction during ageing (Fig. 4a), especially in the long-lived daf-2 
mutant worms166. The decline in ribosome abundance may function as an adaptive 
response to the increased proteotoxic challenges that occur in ageing. Attenuating 
global translation reduces the production of faulty proteins, thereby easing the burden 
on molecular chaperones and degradation systems. Indeed, transient inhibition of 
translation via phosphorylation of translation initiation factor 2α (eIF2α) is an 
important strategy to protect cells from protein misfolding stress187 and is prominently 
associated with the unfolded protein response of the ER and the integrated stress 
response 31,188. Reduction of protein synthesis has beneficial effects, including 
lifespan extension in worms189-192. 
An imbalance between the production of misfolded proteins and available 
proteasome capacity is implicated in various age-related pathologies128,193, and a 
decline in proteasome function has been observed during ageing in model organisms 
in various tissues and cell types194-196. In C. elegans, the abundance of proteasomal 
subunits was found to increase with age166 (Fig. 4a), apparently reflecting an attempt 
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of the organism at removing aberrant protein species. Upregulation of proteasomes 
was further enhanced in the daf-2 mutant.  
 
Adaptations in the chaperone network. 
During human brain ageing, the expression of ATP-dependent chaperones (HSP70 
and HSP60) is repressed, which may contribute to the decline of the capacity to 
counteract protein misfolding175. Notably, in C. elegans, the levels of HSP70 and 
HSP90 chaperones as well as their co-chaperones change only moderately during 
ageing165,166, whereas multiple sHSP increase dramatically (~15-60-fold), especially 
in the daf-2 mutant166, along with proteins involved in oxidative stress defence that 
prevent oxidative stress and resulting protein damage166 (Fig. 4a). Upregulation of 
sHSP is also observed in D. melanogaster197, as well as in mammalian skeletal 
muscle198 and brain during ageing170, suggesting that it is a general phenomenon.  
 
Controlled protein aggregation. 
During ageing in C. elegans several types of sHSP were found to be highly insoluble 
with a high rate of accumulation in the aggregate fraction166 (Fig. 4b). Similar 
observations have been made in vertebrate systems, including human skeletal muscle 
as well as in bacteria 198-200. The recruitment of these chaperones into the insoluble 
fraction may reflect a controlled attempt of the organism to sequester protein 
aggregates, consistent with age-dependent formation of aggregates (as inclusion 
bodies) being a regulated, protective response to lower the pressure on the 
proteostasis network166. The age-dependent increase in sHSP levels may thus reflect a 
shift in defence strategies from preventing aggregation to selective sequestration of 
dangerous protein species in aggregate deposits (Fig. 4b). In support of this 
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possibility, enhanced aggregation of a subset of proteins with an enrichment of 
unstructured regions, along with certain sHSP, was observed in long-lived daf-2 
mutant worms166. Indeed, overexpression of a sHSP (HSP-16) is sufficient to extend 
the lifespan of C. elegans201. This hyper-aggregation under control of insulin/IGF-1 
signalling may be a failsafe protective mechanism to reduce the concentration of 
potentially harmful oligomeric aggregate species, when the first-line defences to 
prevent aggregation — including prevention of misfolding and remodelling of 
misfolded proteins — fail202-204. These findings are consistent with the view that 
soluble oligomers are the major proteotoxic species in neurodegenerative diseases and 
that their sequestration into insoluble aggregates reduces proteotoxicity (Fig. 3). 
 
Conclusions and perspective 
Proteins are essential for most cellular functions. To maintain a functional and 
balanced proteome cells invest in an extensive machinery comprising molecular 
chaperones, proteases and other factors. While this sophisticated machinery is 
sufficient to fulfill its task in young and healthy individuals, its activity declines over 
time and at some point is no longer able to combat the accumulated effects of 
proteotoxic insults. As a consequence, ageing is associated with loss of proteome 
balance and widespread protein aggregation, facilitating the development of 
degenerative pathologies, such as Alzheimer or Parkinson disease. 
 As shown first in a mouse model of Huntington disease, the proteostasis 
network is able to clear aggregates when further synthesis of mutant protein is 
blocked, allowing the (partial) reversal of disease phenotypes140. Accordingly, 
reducing the expression of aggregation-prone proteins with antisense oligonucleotides 
has been shown to be beneficial, even when aggregates have already formed139,205. 
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Other approaches are the removal of toxic aggregates using specific antibodies and 
clearance of aggregate-antibody complexes through phagocytosis206,207 or the use of 
small-molecule kinetic stabilizers that bind the native state of disease proteins and 
prevent their aggregation. A successful example of this latter approach is the small 
molecule Tafamidis that stabilizes transthyretin tetramers and prevents their 
dissociation, which is the rate limiting step in transthyretin amyloidogenesis208. 
However, all these approaches are disease specific and in some cases limited to a 
particular protein mutation. In contrast, augmentation of the proteostasis network has 
the potential to provide a general means to postpone a range of age-related 
degenerative conditions or slow their progression209. Notably, germ cells and some 
stem cells have mastered the unlimited propagation and preservation of a healthy 
proteome. This would suggest that it is possible to carefully augment the proteostasis 
network and thereby delay the onset or slow the progression of age-dependent 
degenerative diseases. In principle, this may be achieved by pharmacologically 
modulating the transcriptional circuits that regulate the different arms of the 
proteostasis network210. 
Increasing organismal protein folding capacity is one potential approach to 
enhance proteostasis capacity. Expression of individual chaperones and co-
chaperones or pharmacologic activation of stress responses (heat shock response, 
unfolded protein response) have been demonstrated to ameliorate phenotypes 
associated with protein aggregation in cellular and organismal models including yeast, 
C. elegans, D. melanogaster, mammalian cells and the mouse129,130,211-220. 
Furthermore, the exogenous delivery of a recombinant fragment of the chaperonin 
TRiC/CCT was shown to modulate cellular phenotypes of Huntington disease221. 
Downregulating protein synthesis, thereby reducing the pressure on the chaperone 
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machinery, is another strategy to improve proteome quality, mimicking the 
attenuation of translation associated with activation of unfolded protein response 
pathways187,222. 
Enhancing the cellular capacity to dispose of toxic protein species by 
upregulating proteolytic activity is yet another way to boost the cellular capacity to 
maintain proteostasis. Small molecule inducers of autophagy, such as rapamycin (and 
its analogs), show benefits in animal models of different neurodegenerative 
diseases223. Accelerated degradation of proteasomal substrates may result from 
inhibition of deubiquitylating enzymes224 or upregulation of proteasome 
assembly178,225. 
Notably however, modulation of the proteostasis network comes at a cost, as it 
has been pointed out that increasing proteostasis capacity and stress resistance may 
favour cancer progression226. This pro-tumorigenic effect stems from the fact that 
cancer cell proliferation depends on the function of multiple mutant proteins that 
require stabilization by the chaperone network227. Accordingly, inhibition of 
chaperones such as HSP90 may be beneficial in the treatment of certain cancers228.  
Overall, as our understanding of the cellular and organismal proteostasis 
networks improves further, there is justified hope that this knowledge will result in 
actual benefits to patients with degenerative diseases resulting from protein 
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Box 1 |Ribosomal quality control 
Cells constantly produce faulty mRNA molecules, including truncated and 
prematurely polyadenylated forms that lack a stop codon (non-stop mRNA). Their 
translation results in aberrant nascent polypeptide chains that stall on the ribosome 
and must be degraded by a specialized ribosomal quality control machinery 
(RQC)63,229. Ribosome stalling and RQC can also occur due to inhibitory mRNA 
stem-loop structures and suboptimal decoding of mRNA codons at the ribosome (no-
go mRNAs). In the case of premature polyadenylation, translation of the polyA tail 
generates a C-terminal polylysine tract, which may aggravate stalling in the 
negatively charged ribosomal tunnel. In the yeast Saccharomyces cerevisiae, the RQC 
machinery comprises the E3 ubiquitin ligase Ltn1, the nucleotide-binding protein 
Rqc2 (NEMF in human), Rqc1 (TCF25 in human) and the AAA+ ATPase Cdc48 
(VCP or P97 in human) and its cofactors230,231. The stalled ribosome is recognized by 
the ubiquitin ligase Hel2 (Znf598 in mammals) and splitting factors. Rqc2 binds the 
60S subunit containing the stalled nascent chain and recruits Ltn1. Rqc2 elongates the 
stalled chain in a mRNA independent fashion by adding Ala and Thr residues to its C-
terminus (so-called CAT-tails)232,233. Ltn1 ubiquitylates the stalled chain for 
recognition and extraction by Cdc48 (dependent on Rqc1), followed by proteasomal 
degradation. Deletion of Ltn1 causes stalled proteins to aggregate in a manner 
mediated by their CAT-tails64,65,234. In yeast cells these aggregates cause impairment 
of the proteostasis network by sequestering chaperone regulators, such as the Hsp40 
Sis164,65. Mutation of Ltn1 causes neurodegeneration in a mouse model67. 
N-terminal signal sequences of stalled nascent chains can drive their import 
into mitochondria or ER. The cytosolic protein Vms1 is an additional RQC 
component protecting mitochondria against toxic effects of CAT-tail aggregates235. 
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Vms1 binds to the outer mitochondrial membrane (OM)236 and antagonizes the 
function of Rqc2 on 60S ribosomes at the OM235 by acting as a peptidyl-tRNA 
hydrolase237,238. As a result, stalled chains are released for import into the 
mitochondria before CAT-tails can be synthesized. 
 
Box 2 |Signalling pathways that modulate ageing and proteostasis 
Studies in model organisms showed that ageing and longevity are genetically 
regulated. Lifespan extension is achieved in three main ways: inhibition of the 
insulin/insulin-like growth factor 1 signalling (IIS) pathway, reduction of food intake, 
or attenuation of the mitochondrial electron transport chain (ETC). 
Insulin/insulin-like growth factor-1 signalling   
Identified in Caenorhabditis elegans as a lifespan-regulating signalling pathway183, 
IIS is conserved from worms to human and controls ageing, stress resistance and 
proteostasis by negatively regulating the nuclear translocation of transcription factors 
DAF-16 (FOXO; forkhead box O in mammals), HSF-1 (heat shock transcription 
factor-1) and SKN-1 (NRF-1; nuclear respiration factor 2 in mammals), which induce 
the expression of protective stress response pathways, such as the upregulation of 
chaperones and proteins protecting against oxidative damage (see Figure). Binding of 
insulin/insulin-like ligands to the DAF-2 receptor activates its tyrosine kinase activity 
and recruits AGE-1 (PI3K; phosphatidylinositol 3-kinase in mammals). This 
ultimately leads to phosphorylation of the downstream transcription factors, 
preventing their translocation into the nucleus. In contrast, reduced IIS in daf-2 or 
age-1 mutant worms blocks this phosphorylation, allowing entry of DAF-16, HSF1 
and SKN-1 into the nucleus for induction of genes required for extending lifespan and 




Dietary restriction (i.e. reduced food intake without malnutrition) is the most robust 
intervention to increase lifespan and delay age-related dysfunction from yeast to 
mammals. In C. elegans, various cellular energy sensors such as AMPK (AMP-
activated protein kinase) and TOR (target of rapamycin) mediate the beneficial effects 
of dietary restriction, supporting activation of PHA-4 (FOXOA in mammals), DAF-
16, HSF-1 and SKN-1. In addition, dietary restriction has been shown to induce 
autophagy.  
Mitochondrial electron transport chain  
Mutations affecting the mitochondrial ETC increase lifespan in C. elegans239-241. Such 
mutations cause (partial) uncoupling of the ETC and production of reactive oxygen 
species (ROS), which upregulates the mitochondrial unfolded protein response 
(UPRMito). As long as ROS production is limited, this mechanism leads to a beneficial 
effect (hormesis). Details of the signalling pathways involved are just emerging: 
Mitochondrial stress causes chromatin remodeling in C. elegans, which is required for 
activation of UPRMito and stress-induced longevity. Two conserved histone lysine 
demethylases function as positive regulators of the ETC longevity pathway241-243. 
Recently it has been reported that mild mitochondrial stress is sufficient to maintain 
proteostasis, healthspan and stress resistance in an HSF1-dependent manner244, 




Figure 1 |The proteostasis network prevents the formation of toxic aggregates 
 (a) The proteostasis network contains all the factors that are necessary to control the 
functional levels of proteins in their native state and minimize non-productive or 
harmful off-pathway reactions (generation of unfolded proteins or aggregates; red). 
Proteostasis network components, which comprise approximately 2000 proteins in 
human cells, can be operationally assigned to three major arms: protein synthesis and 
folding (green), conformational maintenance (blue) and degradation (purple). In 
humans approximately 300 different molecular chaperones175 orchestrate these 
processes and function in folding, refolding and disaggregation reactions. They 
cooperate with the ubiquitin proteasome system and the autophagy–lysosomal 
machinery in the degradation of misfolded proteins and aggregates. (b) Proteins 
sample diverse conformations during folding, increasingly forming native 
intramolecular contacts as they progress downhill along a rugged energy landscape 
towards the thermodynamically stable, native state. Folding intermediates and 
misfolded states may accumulate as kinetically trapped species that need to traverse 
free energy barriers to form functional proteins. Intermolecular contacts between non-
native states may result in formation of various aggregates, oligomers, amorphous 
aggregates and amyloid fibrils, of which the latter may even be thermodynamically 
more stable than the native state. Molecular chaperones enhance on-pathway reactions 
that support progression of folding intermediates towards the native state and block 
off-pathway reactions that lead to misfolded and aggregated species. Various factors, 
such as mutations, stress, translation aberrations or defects in mRNA inhibit the on-




Figure 2 | Mechanisms of aggregate toxicity 
(a) Oligomeric aggregates may form pores in cellular membranes105,106 (left panel), 
while fibrillar aggregates can interact with and deform membranes108,109 (right panel). 
(b) Chronic expression of aberrantly folded proteins caused by disease, ageing or 
external stress reduces proteostasis capacity by sequestering or otherwise inhibiting 
proteostasis network components, including (but not limited to) proteasomes126,127, 
chaperones119,120, nucleocytoplasmic transport factors 111 and factors necessary to 
mount a successful stress response115,121. This will result in further misfolding and 
aggregation of endogenous proteins. These additional misfolded species in turn 
engage the proteostasis network, thereby further reducing available proteostasis 
capacity and driving a positive feedback loop that eventually leads to proteostasis 
collapse. 
 
Figure 3 | Mechanisms to counteract aggregate toxicity 
Cells employ various strategies to counteract the accumulation of toxic protein 
aggregates. Chaperones function to prevent aggregate formation, disassemble 
preexisting aggregates and facilitate the refolding of disaggregated proteins to the 
native state, or conformationally remodel toxic aggregates into less toxic or non-toxic 
forms. Notably, chaperone-mediated disaggregation of more complex aggregates such 
as amyloid fibres is linked to the generation of smaller oligomers, which are 
potentially more toxic than the larger aggregates. Thus, disassembly should be 
coupled to efficient degradation of abnormal protein species. Alternatively, the 
interactive surface area of the aggregate can be reduced by concentrating oligomeric 
species into large inclusions, which may contain fibrillar or amorphous aggregate 
material, or by shielding the aggregate surface with chaperones such as small heat 
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shock proteins (sHSP). Aggregation-prone proteins can also be sequestered in sub-
cellular locations, such as the nucleus or mitochondria, which show a higher tolerance 
for aggregation-prone proteins than the cytosol. In dividing cells it is also possible to 
retain the aggregated proteins in only one of the daughter cells through asymmetric 
cell division, thereby generating a rejuvenated daughter cell.  
 
Figure 4 | Pro-longevity changes in the proteostasis network during ageing in C. 
elegans  
(a) Schematics representing changes in abundance of cytosolic and mitochondrial 
ribosomes, molecular chaperones (small heat shock proteins (sHSP) and HSP70–
HSP90 system), oxidative defence machinery and proteasome complexes in wild-type 
and long-lived daf-2 mutant Caenorhabditis elegans worms as the animals age from 
day 1 of adulthood to day 22 (based on data from ref. 166). Note that despite the 
increased abundance of the components of proteostasis networks, the activity of these 
mechanisms may nevertheless be insufficient to counteract the burden of misfolded 
proteins in aged wild-type animals. (b) Proteome protective activity of sHSP during 
ageing in wild-type and daf-2 worms. Young adult worms maintain a balanced 
proteome by effectively clearing misfolded proteins. Ageing is associated with 
proteome imbalance, due to inefficient clearance of proteins, misregulated 
transcription and loss of the relative stoichiometries of protein complexes166. This 
results in supersaturation171,172 and aggregation of a subset of proteins and the 
accumulation of potentially toxic oligomer species. sHSP increase in abundance 
during ageing and have a protective role by sequestering soluble oligomers into 
insoluble inclusions and by shielding interactive aggregate surfaces. The stronger 
upregulation of sHSP in the daf-2 mutant allows for more effective sequestration of 
50 
 
potentially dangerous aggregate material, maintaining proteome balance as the 
animals age. 
 
Table 1: Main chaperone families and their functions in eukaryotes 
 






Major chaperone family, comprising at least 
eight homologous chaperone proteins located 
in the cytoplasm, mitochondria and the ER. 
These chaperones are required for 
aggregation prevention, folding of newly-
synthesized proteins and for conformational 
maintenance. They also cooperate with 
HSP40 and HSP110 in protein 
disaggregation.  
HSP40 (also known as J proteins) 
~40 kDa 
A diverse group of proteins, all containing the 
HSP70-interacting J-domain, with 
homologues in the cytoplasm, mitochondria 
and the ER. They function as co-chaperones 
of HSP70 and regulators of the HSP70 
ATPase cycle of protein substrate binding and 
release. They recruit HSP70 to different 
substrates and cellular locations.  
HSP110 
~100 kDa 
Serves as a nucleotide exchange factor for 
HSP70. Cooperates with HSP70 in protein 
folding, degradation of misfolded proteins 





Functions as a homodimer in the folding and 
conformational regulation of functionally and 
structurally diverse client proteins that are 
involved in many different cellular pathways. 
Major substrate classes are kinases, steroid 
receptor molecules and other signaling 
proteins. Cooperates with multiple co-
chaperones containing TPR (tetratricopeptide 
repeat) domains. 
HSP60 
~60 kDa subunit 
ATP-dependent 
The chaperonin of mitochondria. Consists of 
two heptameric rings composed of ~60 kDa 
subunits, which are stacked back-to-back. 
Cooperates with a cofactor, HSP10, and is 
required for the folding of a subset of 
mitochondrial proteins following their import 
from the cytosol.  
TRiC/CCT 
~1 MDa 
The chaperonin of the eukaryotic cytosol. 
Consists of two octameric rings composed of 
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ATP-dependent ~60 kDa subunits, which are stacked back-to-
back. Required for the folding of a subset of 
cytosolic proteins, including actin and 
tubulins. TRiC has also been shown to 
interfere with the aggregation of Huntingtin. 
Hsp100  
~100 kDa subunit 
ATP-dependent 
A family of proteins in fungi, bacteria and 
chloroplasts in plants (comprising Hsp104, 
Hsp78, ClpA, ClpB, ClpC, ClpX and HsIU) 
that belongs to a large superfamily of AAA+ 
ATPases. These chaperones are typically 
composed of hexameric rings. Hsp104 in 
yeast and other fungi mediates protein 
disaggregation in cooperation with Hsp70 and 
Hsp40. 
Small HSP 
~12-45 kDa subunit 
ATP-independent chaperones that form large 
(~1 MDa) heterogeneous oligomers. Subunits 
contain a conserved α-crystallin domain, 
which is packed with β-sheets and involved in 
oligomerization. 10 different forms in human 
(HspB1-10). Prevent aggregation by binding 
to non-native states (‘holdase’-function) in 
aggregation prevention but also mediate 










Intrinsically disordered regions 
Regions of a protein that lack stable, well-defined tertiary structure; often functionally 
relevant in interactions with partner proteins. 
Tail-anchored proteins 
Membrane proteins that are post-translationally inserted into the membrane. They 
contain a transmembrane sequence near the carboxy-terminus. 
E3 ubiquitin ligase 
An enzyme that mediates the transfer of ubiquitin from an E2 ubiquitin-conjugating 
enzyme to a protein substrate. 
E2 ubiquitin-conjugating enzyme 
An enzyme that catalyzes the second step in the enzymatic cascade for the transfer of 
ubiquitin to protein substrates. 
Reticulocyte 
An immature red blood cell. 
Co-chaperone 
A factor that assists or regulates the function of a molecular chaperone; some co-
chaperones also have chaperone activity in binding non-native proteins. 
Chaperone-assisted selective autophagy 
Degradation pathway of chaperone-bound proteins in lysosomes. 
Chaperone-mediated autophagy 
Chaperone-dependent degradation pathway of soluble cytosolic proteins that involves 
translocation of the substrate protein across the lysosomal membrane. 
Endosomal microautophagy 




A fibrillar aggregate, composed of polypeptides forming cross- structure that has 
defined tinctorial (dye-binding) properties. 
Low complexity domains 
Sequences of low amino acid diversity that are often intrinsically unstructured . 
Polyglutamine (polyQ) expansion 
Pathogenic elongation of a polyglutamine stretch in a protein caused by an increased 
number of CAG trinucleotide repeats; described in a group of unrelated genes. 
Chaperonin 
A class of molecular chaperones forming large, double-ring complexes that 
transiently enclose substrate protein for folding (examples include HSP60 in 
mitochondria and TRiC/CCT in the eukaryotic cytosol). 
BRICHOS domain 
A domain found in several proteins associated with dementia, respiratory distress and 
cancer, including BRI2, Chondromodulin-I and surfactant protein C. BRICHOS 
domains have intramolecular chaperone-like activities and inhibit misfolding and 
aggregation 
Critical concentration 
The concentration up to which a protein remains soluble; exceeding this concentration 
results in insolubility and aggregation. 
Unfolded protein response 
Cellular stress response pathways that serve to increase protein folding capacity of the 
endoplasmic reticulum (UPRER) or the mitochondria (UPRMito). 
Integrated stress response 
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A conserved signalling pathway that responds to a variety of cellular conditions and 
attenuates protein translation via phosphorylation of the translation initiation factor 
eIF2α. 
Transthyretin 
Tetrameric transport protein that binds the thyroid hormone thyroxin and retinol-
binding protein. Mutant forms dissociate into subunits and aggregate, resulting in 
transthyretin amyloidosis.  
Hormesis 
An adaptive response of an organism or biological system towards a low dose of a 
toxic agent or physical conditions (e.g. reactive oxygen radicals or thermal stress) that 
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